AI Article Synopsis

  • Endogenous oxalate synthesis is a key factor in calcium oxalate stone disease, particularly in inherited conditions like primary hyperoxaluria (PH), but its mechanisms are not fully understood.
  • A study involving 28 participants measured how hydroxyproline (Hyp) metabolism contributes to the formation of oxalate and glycolate through intravenous infusions, revealing significant differences between healthy individuals and those with various types of PH.
  • Results showed that Hyp metabolism is a significant source of urinary oxalate in individuals with PH, especially PH2 and PH3; however, the main sources of oxalate in PH1 patients remain unidentified.

Article Abstract

Endogenous oxalate synthesis contributes to calcium oxalate stone disease and is markedly increased in the inherited primary hyperoxaluria (PH) disorders. The incomplete knowledge regarding oxalate synthesis complicates discovery of new treatments. Hydroxyproline (Hyp) metabolism results in the formation of oxalate and glycolate. However, the relative contribution of Hyp metabolism to endogenous oxalate and glycolate synthesis is not known. To define this contribution, we performed primed, continuous, intravenous infusions of the stable isotope [N,C]-Hyp in nine healthy subjects and 19 individuals with PH and quantified the levels of urinary C-oxalate and C-glycolate formed using ion chromatography coupled to mass detection. The total urinary oxalate-to-creatinine ratio during the infusion was 73.1, 70.8, 47.0, and 10.6 mg oxalate/g creatinine in subjects with PH1, PH2, and PH3 and controls, respectively. Hyp metabolism accounted for 12.8, 32.9, and 14.8 mg oxalate/g creatinine in subjects with PH1, PH2, and PH3, respectively, compared with 1.6 mg oxalate/g creatinine in controls. The contribution of Hyp to urinary oxalate was 15% in controls and 18%, 47%, and 33% in subjects with PH1, PH2, and PH3, respectively. The contribution of Hyp to urinary glycolate was 57% in controls, 30% in subjects with PH1, and <13% in subjects with PH2 or PH3. Hyp metabolism differs among PH types and is a major source of oxalate synthesis in individuals with PH2 and PH3. In patients with PH1, who have the highest urinary excretion of oxalate, the major sources of oxalate remain to be identified.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054332PMC
http://dx.doi.org/10.1681/ASN.2017040390DOI Listing

Publication Analysis

Top Keywords

subjects ph1
16
oxalate synthesis
12
hyp metabolism
12
contribution hyp
12
oxalate/g creatinine
12
ph1 ph2
12
ph2 ph3
12
primary hyperoxaluria
8
endogenous oxalate
8
oxalate glycolate
8

Similar Publications

Background: While both cellular and humoral immunity are important in immunologic protection against influenza, how the influenza-specific CD4 T cell response is established in response to early vaccination remains inadequately understood. In this study, we sought to understand how the CD4 T cell response to inactivated influenza vaccine (IIV) is established and develops throughout early childhood.

Methods: Influenza-specific CD4 T cell responses were quantified following IIV over 2 influenza seasons in 47 vaccinated children between 6 months and 8 years of age who had no documented history of natural influenza infection during the study.

View Article and Find Full Text PDF

Expanding the Genetic Spectrum of Gene Variants in Egyptian Patients with Primary Hyperoxaluria Type I.

Genet Test Mol Biomarkers

April 2024

Department of Clinical and Chemical Pathology, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.

Approximately 80% of primary hyperoxaluria cases are caused by primary hyperoxaluria type 1 (PH1, OMIM# 259900), which is characterized by pathogenic variants in the gene, resulting in deficiency of the liver-specific enzyme alanine-glyoxylate aminotransferase (AGT). This leads to increased production of oxalate, which cannot be effectively eliminated from the body, resulting in its accumulation primarily in the kidneys and other organs. This study included 17 PH1 Egyptian patients from 12 unrelated families, recruited from the Inherited Kidney Disease Outpatient Clinic and the Dialysis Units, Cairo University Hospitals, during the period from January 2018 to December 2019, aiming to identify the pathogenic variants in the gene.

View Article and Find Full Text PDF

This study is aimed to evaluate the safety, tolerability, and pharmacokinetics (PK), as well as to select an appropriate dosing regimen for the pivotal clinical trial of GST-HG171, an orally bioavailable, potent, and selective 3CL protease inhibitor by a randomized, double-blind, and placebo-controlled phase I trial in healthy subjects. We conducted a Ph1 study involving 78 healthy subjects to assess the safety, tolerability, and PK of single ascending doses (150-900 mg) as well as multiple ascending doses (MADs) (150 and 300 mg) of GST-HG171. Additionally, we examined the food effect and drug-drug interaction of GST-HG171 in combination with ritonavir through a MAD regimen of GST-HG171/ritonavir (BID or TID) for 5 days.

View Article and Find Full Text PDF

Background: Without effective intervention, primary hyperoxaluria type 1 (PH1) causes oxalate-induced kidney damage, leading to end-stage kidney disease and serious complications throughout the body. Although PH1 carries a heavy burden that impacts quality of life, literature on the experiences of those living with PH1 and caring for patients with PH1 is limited. This study aimed to describe the diagnostic journey in PH1 and characterize patients' and caregivers' self-reported experiences throughout the disease course.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!